Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

• Published in: Future oncology (London, England) Vol. 19; no. 14; pp. 961 - 973
• Main Authors: Solomon, Benjamin J, Bauer, Todd M, K Mok, Tony S, Liu, Geoffrey, Mazieres, Julien, Marinis, Filippo de, Goto, Yasushi, Kim, Dong-Wan, Wu, Yi-Long, Jassem, Jacek, López, Froylán López, Soo, Ross A, Shaw, Alice T, Polli, Anna, Messina, Rossella, Iadeluca, Laura, Toffalorio, Francesca, Felip, Enriqueta
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.05.2023
• Subjects: CROWN; lorlatinib; non-small-cell lung cancer; Plain language summary; CROWN; lorlatinib; Plain language summary; non-small-cell lung cancer
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2022-1289

This summary shows the updated results of an ongoing research study called CROWN that was published in in December 2022. In the CROWN study, researchers looked at the effects of two study medicines called lorlatinib and crizotinib. The study included people with advanced non-small-cell lung cancer (NSCLC) that had not been treated previously. All people in the study had cancer cells with changes (known as alterations) in a gene called , or . This gene is involved in cancer growth. In this updated study, researchers looked at the continued benefit in people who took lorlatinib compared with people who took crizotinib after 3 years. After 3 years of being observed, people who took lorlatinib were more likely to be alive without their cancer getting worse than people who took crizotinib. At 3 years, 64% of people who took lorlatinib were alive without their cancer getting worse compared with 19% of people who took crizotinib. The cancer was less likely to have spread within or to the brain in people who took lorlatinib than in people who took crizotinib. After 3 years of being observed, 61% of people were still taking lorlatinib and 8% of people were still taking crizotinib. People who took lorlatinib had more severe side effects than people who took crizotinib. However, these side effects were manageable. The most common side effects with lorlatinib were high levels of cholesterol or high levels of triglycerides (a type of fat) in the blood. Life-threatening side effects were seen in 13% of people who took lorlatinib and 8% in crizotinib. Two people who took lorlatinib died because of side effects from lorlatinib. The updated results from the CROWN study showed that a larger percentage of people who took lorlatinib continued to benefit from their treatment after being observed for 3 years compared with those who took crizotinib.